BioLineRx Ltd.

1.76-0.0600-3.30%Vol 748.94K1Y Perf 96.76%
Oct 2nd, 2023 16:00 DELAYED
BID1.68 ASK1.83
Open1.80 Previous Close1.82
Pre-Market- After-Market1.82
 - -  0.06 3.41%
Target Price
9.67 
Analyst Rating
Strong Buy 1.00
Potential %
449.43 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★ —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
61.21 
Earnings Rating
Strong Sell
Market Cap108.29M 
Earnings Date
21st Nov 2023
Alpha-0.03 Standard Deviation0.21
Beta1.80 

Today's Price Range

1.681.83

52W Range

0.54502.53

5 Year PE Ratio Range

-2.90-1.40

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
-8.81%
1 Month
-12.87%
3 Months
8.64%
6 Months
82.88%
1 Year
96.76%
3 Years
12.10%
5 Years
-91.24%
10 Years
-95.62%

TickerPriceChg.Chg.%
BLRX1.76-0.0600-3.30
AAPL173.752.54001.48
GOOG135.173.32002.52
MSFT321.806.05001.92
XOM115.63-1.9500-1.66
WFC39.61-1.2500-3.06
JNJ155.15-0.6000-0.39
FB196.640.99000.51
GE108.79-1.7600-1.59
JPM143.77-1.2500-0.86
Financial StrengthValueIndustryS&P 500US Markets
7.10
7.10
0.15
0.19
-22.20
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
-
-
-
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2023-0.16-0.30-87.50
Q01 2023-0.14-0.15-7.14
Q04 2022-0.14-0.0935.71
Q03 2022-0.16-0.156.25
Q02 2022-0.14-0.16-14.29
Q01 2022-0.15-0.1033.33
Q04 2021-0.14-0.0842.86
Q03 2021-0.13-0.23-76.92
Earnings Per EndEstimateRevision %Trend
9/2023 QR-0.18-12.50Negative
12/2023 QR-0.18-12.50Negative
12/2023 FY-0.83-27.69Negative
12/2024 FY-0.30-100.00Negative
Next Report Date21st Nov 2023
Estimated EPS Next Report-0.18
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume748.94K
Shares Outstanding61.53K
Shares Float60.55M
Trades Count2.47K
Dollar Volume1.32M
Avg. Volume1.46M
Avg. Weekly Volume821.59K
Avg. Monthly Volume2.44M
Avg. Quarterly Volume1.12M

BioLineRx Ltd. (NASDAQ: BLRX) stock closed at 1.76 per share at the end of the most recent trading day (a -3.3% change compared to the prior day closing price) with a volume of 748.94K shares and market capitalization of 108.29M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 38 people. BioLineRx Ltd. CEO is Philip Serlin.

The one-year performance of BioLineRx Ltd. stock is 96.76%, while year-to-date (YTD) performance is 198.31%. BLRX stock has a five-year performance of -91.24%. Its 52-week range is between 0.545 and 2.53, which gives BLRX stock a 52-week price range ratio of 61.21%

BioLineRx Ltd. currently has a PE ratio of -1.30, a price-to-book (PB) ratio of 0.66, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -30.30%, a ROC of -32.28% and a ROE of -40.70%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from BioLineRx Ltd., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.18 for the next earnings report. BioLineRx Ltd.’s next earnings report date is 21st Nov 2023.

The consensus rating of Wall Street analysts for BioLineRx Ltd. is Strong Buy (1), with a target price of $9.67, which is +449.43% compared to the current price. The earnings rating for BioLineRx Ltd. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BioLineRx Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BioLineRx Ltd. has a Neutral technical analysis rating based on Technical Indicators (ADX : 17.20, ATR14 : 0.20, CCI20 : -132.79, Chaikin Money Flow : -0.17, MACD : 0.06, Money Flow Index : 47.43, ROC : 0.00, RSI : 46.14, STOCH (14,3) : 16.92, STOCH RSI : 0.00, UO : 48.24, Williams %R : -83.08), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BioLineRx Ltd. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

BioLineRx Ltd.

BioLine Rx Ltd is a clinical-stage biopharmaceutical development company with a strategic focus on oncology. Its development and commercialization pipeline consists of two clinical-stage therapeutic candidates - Motixafortide, a novel peptide for the treatment of solid tumors, hematological malignancies and stem cell mobilization, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, it has an off- strategy, a legacy therapeutic product called BL-5010 for the treatment of skin lesions.

CEO: Philip Serlin

Telephone: +972 86429100

Address: 2 HaMa'ayan Street, Modi'in 7177871, , IL

Number of employees: 38

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

52%48%

Bearish Bullish

55%45%

Bearish Bullish

59%41%

 

News

Stocktwits